ABSTRACT
Peanut allergy poses a significant global health concern, triggering hypersensitivity reactions upon exposure to peanuts. Understanding the molecular mechanisms governing peanut-specific immune responses is imperative for developing effective therapeutic approaches. This study aimed to investigate differentially expressed genes (DEGs) and associated molecular pathways implicated in peanut allergy-induced immune responses. Employing a systematic and bioinformatics-driven approach, we analyzed gene expression profiles from peanut-allergic individuals and healthy controls using RNAseq Next-Generation Sequencing (NGS) data. Enrichment analysis of DEGs revealed their involvement in various inflammatory conditions, including autoinflammatory, allergic, and respiratory disorders. Additionally, pathway enrichment analysis highlighted perturbed molecular pathways such as Asthma, IL-17 signaling pathway, and Inflammatory bowel diseases, underscoring their role in modulating peanut-specific immune responses. Protein-protein interaction network analysis identified central regulatory hubs, elucidating the intricate molecular interplay underlying the immune response to peanut allergens. Overall, our findings offer comprehensive insights into the molecular landscape of peanut allergy, delineating key DEGs and pathways associated with peanut-specific immune responses. This systematic and bioinformatics-driven approach enhances our understanding of allergic reactions to peanuts, providing potential targets for the development of novel therapeutic interventions and diagnostic biomarkers for peanut allergy management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://www.ncbi.nlm.nih.gov/sra/?term=SRX14128943
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at https://www.ncbi.nlm.nih.gov/sra/?term=SRX14128943
